For patients with Crohn’s disease, the Institute has the opportunity to participate in a clinical trial of the new drug ustekinumab(Stelara).
Ustekinumab, which was originally developed to treat psoriasis, has been shown to be extremely effective in treating moderate to severe Crohn’s disease. In a phase III clinical trial by Johnson & Johnson, more than 50% of the 629 patients who received a single injection of ustekinumab had a significant reduction in Crohn’s disease index from baseline (100 points or more). .
We invite patients interested in participating in a clinical trial of Crohn’s disease to contact the project coordinator by the following telephone number:
+38 (067) 7238868 – Budzak Igor Yaroslavovich